{"groups":[{"description":"Patients receive crizotinib 250 mg PO BID on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"FG000","title":"Treatment (Crizotinib)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"4"}],"type":"Ineligible or Never Started"},{"reasons":[{"groupId":"FG000","numSubjects":"12"}],"type":"Mutation Status Not Confirmed"},{"reasons":[{"groupId":"FG000","numSubjects":"4"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"19"}],"type":"Disease Progression"},{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"Other Complicating Disease"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"On Treatment"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"44"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"40"}],"type":"Started Protocol Therapy"},{"achievements":[{"groupId":"FG000","numSubjects":"28"}],"comment":"Primary efficacy analysis set","type":"Eligible, Treated and Mutation Status Confirmed"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"44"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"For subprotocol C1, patients were required to have MET amplification defined as ≥7 copies/cell as identified by the Oncomine® Assay, or the Oncomine® Assay equivalent of 7 or greater as identified by a Designated Laboratory.","recruitmentDetails":"Subprotocol C1 was activated on May 31, 2016. Forty-four patients were enrolled on EAY131-C1 between July 29, 2016, and November 12, 2021. Thirteen patients were enrolled on the basis of the results from the NCI-MATCH assay and 31 on the basis of the outside assay results."}